Chugai Pharmaceutical Co., Ltd. (CHGCF) 은(는) 상장 기업입니다 헬스케어 섹터의 제약 산업에서 운영. 본사 소재지는 Chuo, 일본. 현재 CEO는 Osamu Okuda.
CHGCF 을(를) 보유 IPO 날짜 2012-08-03, 5,026 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $90.63B.
Chugai Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacture, and sale of medicines globally. The company maintains a diverse portfolio spanning oncology, immunology, hematology, ophthalmology, and other therapeutic areas, with established products including Tecentriq, Herceptin, Avastin, Rituxan, and Tamiflu. As a subsidiary of Roche Holding Ltd., Chugai leverages strategic alliances within the Roche Group and conducts collaborative research with academic institutions to advance its pipeline of development candidates. Founded in 1925 and headquartered in Chuo, Japan, the company continues to expand its international presence across multiple disease indications.
